Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
629.8
1 302
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 644.39 INR. Compared to the current market price of 949.05 INR, Zydus Lifesciences Ltd is Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zydus Lifesciences Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZYDUSLIFE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing...
Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing patient base globally.
For investors, Zydus Lifesciences presents a compelling opportunity fueled by strategic expansion and strong financial performance. The company's recent foray into the biopharmaceutical sector, backed by successful launches of innovative therapies and the development of complex generics, indicates a clear path for sustainable growth. Moreover, Zydus has demonstrated resilience in navigating regulatory challenges and market fluctuations, enabling it to establish a solid presence in established and emerging markets alike. As healthcare dynamics shift towards personalized medicine and advanced biologics, Zydus is poised not only to adapt but to lead in these areas, making it an enticing consideration for investors looking to be part of a forward-thinking healthcare company with a solid foundation.
Zydus Lifesciences Ltd., formerly known as Zydus Cadila, is a prominent player in the pharmaceutical industry, operating across several core business segments. Here are the main segments:
-
Pharmaceuticals: This is the primary segment of Zydus Lifesciences, focusing on the development, manufacturing, and marketing of generic and branded formulations. The company has a diverse portfolio that includes therapeutic areas such as cardiology, diabetes, gynecology, and oncology.
-
Biologics: Zydus Lifesciences has invested significantly in biotechnology, particularly in the development of monoclonal antibodies and vaccines. The company's biologics segment focuses on producing innovative biologic therapies for various diseases.
-
Consumer Health: This segment encompasses over-the-counter products and health supplements. Zydus Lifesciences aims to address consumer health needs with products focusing on general wellness, nutrition, and specific health issues.
-
Diagnostics: Zydus Lifesciences is involved in the diagnostic segment, offering a range of laboratory tests and diagnostic solutions that enhance patient care and support clinical decision-making.
-
Research and Development (R&D): This segment underlines the company’s commitment to innovation. Zydus Lifesciences focuses on developing new drugs, including novel drug delivery systems, and has dedicated R&D facilities for both pharmaceuticals and biologics.
-
International Operations: Zydus Lifesciences has a strong international presence, exporting products to various markets, including the US, Europe, Africa, and Asia. This segment is crucial for the company's growth strategy, focusing on regulatory compliance and localization of products.
These segments collectively contribute to Zydus Lifesciences’ mission of making healthcare accessible and affordable while adhering to high-quality standards. The company’s strategic focus on innovation, expansion into new markets, and diversification of its product portfolio are key drivers of its growth.
Zydus Lifesciences Ltd, an Indian pharmaceutical company, boasts several unique competitive advantages that set it apart from its rivals. Here are some key aspects:
-
Diversified Product Portfolio: Zydus Lifesciences has a broad range of products spanning generic drugs, biosimilars, vaccines, and consumer healthcare products. This diversification helps mitigate risks associated with dependency on a single revenue stream.
-
Strong R&D Capabilities: The company invests significantly in research and development, allowing it to innovate and develop new drugs. Its robust pipeline of potential new products, especially in areas like biologics and biosimilars, provides it with a competitive edge.
-
Manufacturing Excellence: Zydus has a network of state-of-the-art manufacturing facilities certified by regulatory authorities worldwide. This capability not only ensures high-quality production standards but also enhances efficiency, enabling the company to meet regulatory compliance and deliver products reliably.
-
Global Presence: The company has established a significant international footprint, exporting products to over 100 countries. This global outreach reduces reliance on the Indian market and allows it to capitalize on growth opportunities in various regions.
-
Strategic Partnerships and Alliances: Zydus has formed collaborations with other pharmaceutical companies, research institutions, and government organizations. These strategic partnerships enhance its capabilities in drug development and commercialization.
-
Strong Branding and Reputation: With a legacy of over 60 years, Zydus has built a reputable brand associated with quality and efficacy. This reputation can drive customer loyalty and trust, giving it an edge over competitors.
-
Focus on Affordable Healthcare: The company emphasizes affordability, focusing on making healthcare accessible. This approach aligns with global trends towards cost-effective treatments, bolstering its market position.
-
Agile Regulatory Strategy: Zydus has demonstrated an ability to navigate complex regulatory environments effectively. Its proactive approach to compliance and approvals helps expedite time-to-market for new products.
-
Biosimilar Leadership: The company has a strong emphasis on developing biosimilars, which are increasingly vital in the pharmaceutical industry due to the growing demand for biologic therapies. This specialization positions Zydus advantageously as the market for biosimilars expands.
-
Dedicated Consumer Healthcare Division: Zydus has a growing consumer healthcare division that focuses on over-the-counter (OTC) products, allowing it to tap into the health and wellness market and diversify its revenue streams.
Overall, Zydus Lifesciences Ltd’s combination of strong R&D, a diverse product range, manufacturing strengths, and a commitment to affordable healthcare positions it competitively within the pharmaceutical industry.
Zydus Lifesciences Ltd, like many companies in the pharmaceutical and biotechnology sectors, faces several risks and challenges that could impact its operations and growth in the near future:
-
Regulatory Compliance: The pharmaceutical industry is heavily regulated. Zydus must continuously ensure compliance with regulatory requirements in various markets. Any delays or failures in regulatory approvals can affect product launches and revenue.
-
Intellectual Property (IP) Risks: The company relies on patents and IP rights to protect its innovations. Challenges in maintaining these rights or facing patent infringements could lead to increased competition and loss of market share.
-
Market Competition: The pharmaceutical market is highly competitive, with numerous players in generic drugs and innovative therapies. The entry of new competitors, especially in the biotechnology space, can pressure pricing and margins.
-
Supply Chain Disruptions: Global supply chains can be affected by geopolitical tensions, natural disasters, or pandemics, impacting raw material availability and production timelines.
-
Pricing Pressure: Increasing competition and cost-containment efforts by healthcare providers and governments can lead to pricing pressures on Zydus's products, impacting overall profitability.
-
Research and Development (R&D) Risks: The success of new drugs depends on R&D outcomes, which can be unpredictable. Failed trials can lead to substantial financial losses and impact the company's reputation.
-
International Market Exposure: Expanding into new markets introduces challenges such as understanding local regulations, cultural differences, and varying market dynamics, which could hinder growth.
-
Economic Factors: Economic downturns or changes in healthcare policies (such as pricing regulations) in major markets can impact sales and revenues.
-
Technological Advancements: The rapid pace of technological change in healthcare can render existing products obsolete. Zydus must continue to innovate and adapt to stay relevant.
-
Loss of Key Personnel: The pharmaceutical sector relies on skilled scientists and executives. The loss of key personnel could disrupt operations and R&D efforts.
-
Public Perception and Ethical Concerns: Issues related to drug pricing, access to medicines, and ethical marketing practices can adversely affect the company's reputation and operations.
By addressing these risks through strategic planning and operational excellence, Zydus Lifesciences can position itself to navigate these challenges effectively.
Revenue & Expenses Breakdown
Zydus Lifesciences Ltd
Balance Sheet Decomposition
Zydus Lifesciences Ltd
Current Assets | 115B |
Cash & Short-Term Investments | 20.5B |
Receivables | 60.5B |
Other Current Assets | 34.1B |
Non-Current Assets | 177.8B |
Long-Term Investments | 9.7B |
PP&E | 69.1B |
Intangibles | 78.8B |
Other Non-Current Assets | 20.2B |
Current Liabilities | 53.4B |
Accounts Payable | 21.3B |
Accrued Liabilities | 12.7B |
Short-Term Debt | 7.7B |
Other Current Liabilities | 11.8B |
Non-Current Liabilities | 41.1B |
Long-Term Debt | 251m |
Other Non-Current Liabilities | 40.8B |
Earnings Waterfall
Zydus Lifesciences Ltd
Revenue
|
206.2B
INR
|
Cost of Revenue
|
-61.4B
INR
|
Gross Profit
|
144.8B
INR
|
Operating Expenses
|
-93.9B
INR
|
Operating Income
|
50.8B
INR
|
Other Expenses
|
-8.9B
INR
|
Net Income
|
41.9B
INR
|
Free Cash Flow Analysis
Zydus Lifesciences Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY25, the company achieved substantial growth across all segments, with consolidated revenues rising 20% to INR 52.4 billion. The U.S. business surged 30%, driven by product expansions and an increasing portfolio. Margins improved, with EBITDA rising 28% and the margin touching 27.9%. Key initiatives include a joint venture focused on eco-friendly protein production and successful acquisitions like Naturell India. Guidance suggests continued double-digit growth, with FY25 revenue forecasts in the high teens and stable EBITDA margins expected. The innovation pipeline remains robust, with several new product launches anticipated in FY26.
What is Earnings Call?
ZYDUSLIFE Profitability Score
Profitability Due Diligence
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ZYDUSLIFE Solvency Score
Solvency Due Diligence
Zydus Lifesciences Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Zydus Lifesciences Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZYDUSLIFE Price Targets Summary
Zydus Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for ZYDUSLIFE is 1 080.22 INR with a low forecast of 494.9 INR and a high forecast of 1 449 INR.
Dividends
Current shareholder yield for ZYDUSLIFE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZYDUSLIFE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,743 full-time employees. The firm is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The firm has a pipeline for Biologics and Vaccines. The firm offers Lipaglyn to treat diabetic dyslipidemia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The firm in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The firm provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The firm has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.
Contact
IPO
Employees
Officers
The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 644.39 INR.
Compared to the current market price of 949.05 INR, Zydus Lifesciences Ltd is Overvalued by 32%.